PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Panitumumab in RAS Wild-Type Left-Sided mCRC: Evidence Synthesis

panitumumabcetuximabanti-EGFRsotorasibbevacizumabencorafenibKRAS G12CRAS wild-typeBRAF V600EHER2ctDNAmetastatic colorectal cancernarrative reviewprecision oncologytumor sidedness Oncology Pharmacy

Background Information

Panitumumab extends survival in metastatic colorectal cancer with precision therapy advances.

Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related deaths, and targeted therapies like panitumumab offer potential improvements in treatment outcomes. Panitumumab extends overall survival by 5.6 months in first-line treatment. ctDNA analysis predicts treatment eligibility with a 30% response rate observed in rechallenge cases. Panitumumab shows significant efficacy in RAS wild-type mCRC, especially in left-sided tumors. Advances in molecular stratification and ctDNA monitoring can optimize its use. Panitumumab is vital for RAS wild-type mCRC treatment, with precision strategies enhancing its deployment.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Kwiatkowska L, Szczuko M

Citation: Kwiatkowska L, Szczuko M The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer-A Narrative Review of Current Evidence and Emerging Therapeutic Strategies. International journal of molecular sciences. 2026;27(17). doi:10.3390/ijms27177559

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.